New Directions in Gaucher Disease

Human Mutation

Volumn 37, Issue 11, 2016, Pages 1121-1136

  Horowitz, Mia ^a   Elstein, Deborah ^b   Zimran, Ari ^b   Goker Alpan, Ozlem ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c Lysosomal Disorders Unit and Center for Clinical Trials   (United States)

Author keywords

Gaucher disease; glucocerebrosidase; induced pleuripotent stem cells; Parkinson disease; Unfolded Protein Response

Indexed keywords

CHAPERONE;

AUTOPHAGY; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; ENZYME REPLACEMENT; GAUCHER DISEASE; GENETIC ASSOCIATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; MITOPHAGY; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBSTRATE REDUCTION THERAPY; THERAPY; UNFOLDED PROTEIN RESPONSE;

EID: 84991235229     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.23056     Document Type: Review

References (262)

1. Abada A, Elazar Z. 2014. Getting ready for building: signaling and autophagosome biogenesis. EMBO Rep 15:839–852.
2. Abian O, Alfonso P, Velazquez-Campoy A, Giraldo P, Pocovi M, Sancho J. 2011. Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm 8:2390–2397.
3. Abrahamov A, Elstein D, Gross-Tsur V, Farber B, Glaser Y, Hadas-Halpern I, Ronen S, Tafakjdi M, Horowitz M, Zimran A. 1995. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 346:1000–1003.
4. Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, Marugan J, Patnaik S, Maniwang E, Gonzalez AN, Sidransky E. 2016. Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages. Aging Cell 15:77–88.
5. Aflaki E, Stubblefield BK, Maniwang E, Lopez G, Moaven N, Goldin E, Marugan J, Patnaik S, Dutra A, Southall N, Zheng W, Tayebi N, et al. 2014. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med 6:240ra273.
6. Aguilar-Moncayo M, Garcia-Moreno MI, Trapero A, Egido-Gabas M, Llebaria A, Fernandez JM, Mellet CO. 2011. Bicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards beta-glucocerebrosidase. Org Biomol Chem 9:3698–3713.
7. Aguilar-Moncayo M, Takai T, Higaki K, Mena-Barragan T, Hirano Y, Yura K, Li L, Yu Y, Ninomiya H, Garcia-Moreno MI, Ishii S, Sakakibara Y, et al. 2012. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis. Chem Commun (Camb) 48:6514–6516.
8. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. 2004. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351:1972–1977.
9. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, et al. 2010. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 32:775–779.
10. Alfonso P, Pampin S, Estrada J, Rodriguez-Rey JC, Giraldo P, Sancho J, Pocovi M. 2005. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 35:268–276.
11. Alt FW, Kellems RE, Bertino JR, Schimke RT. 1978. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–1370.
12. Andreotti G, Citro V, De Crescenzo A, Orlando P, Cammisa M, Correra A, Cubellis MV. 2011. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests. Orphanet J Rare Dis 6:66.
13. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E. 2009. A plant-derived recombinant human glucocerebrosidase enzyme—a preclinical and phase I investigation. PLoS One 4:e4792.
14. Awad O, Sarkar C, Panicker LM, Miller D, Zeng X, Sgambato JA, Lipinski MM, Feldman RA. 2015. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet 24:5775–5788.
15. Babajani G, Tropak MB, Mahuran DJ, Kermode AR. 2012. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant beta-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant. Mol Genet Metab 106:323–329.
16. Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, Lee SJ. 2015. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp Mol Med 47:e188.
17. Balreira A, Gaspar P, Caiola D, Chaves J, Beirao I, Lima JL, Azevedo JE, Miranda MC. 2008. A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome. Hum Mol Genet 17:2238–2243.
18. Barton NW, Brady RO, Dambrosia JM. 1993. Treatment of Gaucher's disease. N Engl J Med 328:1564–1565; author reply 1567–1568.
19. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH. 2015. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 72:201–208.
20. Beavan MS, Schapira AH. 2013. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45:511–521.
21. Bembi B, Zambito Marsala S, Sidransky E, Ciana G, Carrozzi M, Zorzon M, Martini C, Gioulis M, Pittis MG, Capus L. 2003. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61:99–101.
22. Bendikov-Bar I, Maor G, Filocamo M, Horowitz M. 2013. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis 50:141–145.
23. Bendikov-Bar I, Rapaport D, Larisch S, Horowitz M. 2014. Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS. Orphanet J Rare Dis 9:86.
24. Benito JM, Garcia Fernandez JM, Ortiz Mellet C. 2011. Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin Ther Pat 21:885–903.
25. Berardi AS, Pannuzzo G, Graziano A, Costantino-Ceccarini E, Piomboni P, Luddi A. 2014. Pharmacological chaperones increase residual β-galactocerebrosidase activity in fibroblasts from Krabbe patients. Mol Genet Metab 112:294–301.
26. Bercovich Z, Kahana C. 1993. Involvement of the 20S proteasome in the degradation of ornithine decarboxylase. Eur J Biochem 213:205–210.
27. Berg-Fussman A, Grace ME, Ioannou Y, Grabowski GA. 1993. Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. J Biol Chem 268:14861–14866.
28. Beutler E. 1995. Gaucher disease, a paradigm for single gene defects. Experientia 51:196–197.
29. Beutler E, Beutler L, West C. 2004. Mutations in the gene encoding cytosolic beta-glucosidase in Gaucher disease. J Lab Clin Med 144:65–68.
30. Beutler E, Grabowski GA. 2001. Gaucher disease. The metabolic and molecular basis of inherited diseases. New York: McGraw-Hill. p 3635–3668.
31. Beutler E, Kuhl W. 1986. Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with Type I, Type II, and Type III Gaucher disease. Proc Natl Acad Sci USA 83:7472–7474.
32. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM. 2007. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem 282:1305–1312.
33. Bornstein B, Edison N, Gottfried Y, Lev T, Shekhtman A, Gonen H, Rajalingam K, Larisch S. 2012. X-linked inhibitor of apoptosis protein promotes the degradation of its antagonist, the pro-apoptotic arts protein. Int J Biochem Cell Biol 44:489–495.
34. Bottcher T, Rolfs A, Meyer B, Grossmann A, Berg D, Kropp P, Benecke R, Walter U. 2013. Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol 260:2523–2531.
35. Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA, Valenzano KJ. 2013. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56:2705–2725.
36. Boyd RE, Valenzano KJ. 2014. Correction of lysosomal dysfunction as a therapeutic strategy for neurodegenerative diseases. Bioorg Med Chem Lett 24:3001–3005.
37. Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D. 2015. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 30:407–411.
38. Brumshtein B, Aguilar-Moncayo M, Benito JM, Garcia Fernandez JM, Silman I, Shaaltiel Y, Aviezer D, Sussman JL, Futerman AH, Ortiz Mellet C. 2011. Cyclodextrin-mediated crystallization of acid beta-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues. Org Biomol Chem 9:4160–4167.
39. Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS, Futerman AH. 2010. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20:24–32.
40. Butters TD. 2007. Gaucher disease. Curr Opin Chem Biol 11:412–418.
41. Candi E, Cipollone R, Rivetti di Val Cervo P, Gonfloni S, Melino G, Knight R. 2008. P63 in epithelial development. Cell Mol Life Sci 65:3126–3133.
42. Castilla J, Risquez R, Cruz D, Higaki K, Nanba E, Ohno K, Suzuki Y, Diaz Y, Ortiz Mellet C, Garcia Fernandez JM, Castillon S. 2012. Conformationally-locked N-glycosides with selective beta-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease. J Med Chem 55:6857–6865.
43. Chang HH, Asano N, Ishii S, Ichikawa Y, Fan JQ. 2006. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. FEBS J 273:4082–4092.
44. Cheng WC, Weng CY, Yun WY, Chang SY, Lin YC, Tsai FJ, Huang FY, Chen YR. 2013. Rapid modifications of N-substitution in iminosugars: development of new beta-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease. Bioorg Med Chem 21:5021–5028.
45. Chiasserini D, Paciotti S, Eusebi P, Persichetti E, Tasegian A, Kurzawa-Akanbi M, Chinnery PF, Morris CM, Calabresi P, Parnetti L, Beccari T. 2015. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener 10:15.
46. Chiricozzi E, Niemir N, Aureli M, Magini A, Loberto N, Prinetti A, Bassi R, Polchi A, Emiliani C, Caillaud C, Sonnino S. 2014. Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on beta-hexosaminidase activity in Sandhoff fibroblasts. Mol Neurobiol 50:159–167.
47. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7:1144–1150.
48. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, Vonsattel JP, Fahn S, et al. 2009. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 66:578–583.
49. Clark LN, Nicolai A, Afridi S, Harris J, Mejia-Santana H, Strug L, Cote LJ, Louis ED, Andrews H, Waters C, Ford B, Frucht S, et al. 2005. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord 20:100–103.
50. Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, et al. 2007. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69:1270–1277.
51. Clark NE, Metcalf MC, Best D, Fleet GW, Garman SC. 2012. Pharmacological chaperones for human alpha-n-acetylgalactosaminidase. Proc Natl Acad Sci USA 109:17400–17405.
52. Corti O, Hampe C, Koutnikova H, Darios F, Jacquier S, Prigent A, Robinson JC, Pradier L, Ruberg M, Mirande M, Hirsch E, Rooney T, et al. 2003. The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12:1427–1437.
53. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, et al. 2003. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513–526.
54. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. 2015. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385:2355–2362.
55. Cuervo AM, Wong E. 2014. Chaperone-mediated autophagy: roles in disease and aging. Cell Res 24:92–104.
56. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, et al. 2011. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 69:940–953.
57. Dahl M, Doyle A, Olsson K, Mansson JE, Marques AR, Mirzaian M, Aerts JM, Ehinger M, Rothe M, Modlich U, Schambach A, Karlsson S. 2015. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther 23:835–844.
58. Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. 2009. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell 4:200–201; author reply 202.
59. Dantuma NP, Bott LC. 2014. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci 7:70.
60. Dawson G, Schroeder C, Dawson PE. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem Biophys Res Commun 395:66–69.
61. de Graaf M, van Veen IC, van der Meulen-Muileman IH, Gerritsen WR, Pinedo HM, Haisma HJ. 2001. Cloning and characterization of human liver cytosolic beta-glycosidase. Biochem J 356:907–910.
62. de Ruijter J, Valstar MJ, Wijburg FA. 2011. Mucopolysaccharidosis type III (Sanfilippo syndrome): emerging treatment strategies. Curr Pharm Biotechnol 12:923–930.
63. Dekker N, Voorn-Brouwer T, Verhoek M, Wennekes T, Narayan RS, Speijer D, Hollak CE, Overkleeft HS, Boot RG, Aerts JM. 2011. The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation. Blood Cells Mol Dis 46:19–26.
64. Doty RL, Deems DA, Stellar S. 1988. Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:1237–1244.
65. Du TT, Wang L, Duan CL, Lu LL, Zhang JL, Gao G, Qiu XB, Wang XM, Yang H. 2015. GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 11:1803–1820.
66. Duran R, Mencacci NE, Angeli AV, Shoai M, Deas E, Houlden H, Mehta A, Hughes D, Cox TM, Deegan P, Schapira AH, Lees AJ, et al. 2013. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord 28:232–236.
67. Eblan MJ, Scholz S, Stubblefield B, Gutti U, Goker-Alpan O, Hruska KS, Singleton AB, Sidransky E. 2006. Glucocerebrosidase mutations are not found in association with LRKK2 G2019S in subjects with Parkinsonism. Neurosci Lett 404:163–165.
68. Edison N, Reingewertz TH, Gottfried Y, Lev T, Zuri D, Maniv I, Carp MJ, Shalev G, Friedler A, Larisch S. 2012. Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells. Clin Cancer Res 18:2569–2578.
69. Erickson AH, Ginns EI, Barranger JA. 1985. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J Biol Chem 260:14319–14324.
70. Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S, Futerman AH. 2009. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet 18:1482–1488.
71. Farfel-Becker T, Vitner EB, Futerman AH. 2011. Animal models for Gaucher disease research. Dis Model Mech 4:746–752.
72. Fishbein I, Kuo YM, Giasson BI, Nussbaum RL. 2014. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 137:3235–3247.
73. Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, Kuwahara K, Harada M, Matsuda H, Matsuoka S, Okita K, Takahashi K, et al. 2011. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One 6:e16734.
74. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, et al. 2012. Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ 19:107–120.
75. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A. 2008. Genotype–phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283.
76. Gaspar P, Kallemeijn WW, Strijland A, Scheij S, Van Eijk M, Aten J, Overkleeft HS, Balreira A, Zunke F, Schwake M, Sa Miranda C, Aerts JM. 2014. Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis. J Lipid Res 55:138–145.
77. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW, Schapira AH. 2012. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 72:455–463.
78. Gegg ME, Schapira AH. 2016. Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiol Dis 90:43–50.
79. Germain DP, Fan JQ. 2009. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther 47(Suppl 1):S111–S117.
80. Ginns EI, Brady RO, Pirruccello S, Moore C, Sorrell S, Furbish FS, Murray GJ, Tager J, Barranger JA. 1982. Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. Proc Natl Acad Sci USA 79:5607–5610.
81. Ginns EI, Choudary PV, Tsuji S, Martin B, Stubblefield B, Sawyer J, Hozier J, Barranger JA. 1985. Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease. Proc Natl Acad Sci USA 82:7101–7105.
82. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428.
83. Goddard-Borger ED, Tropak MB, Yonekawa S, Tysoe C, Mahuran DJ, Withers SG. 2012. Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease. J Med Chem 55:2737–2745.
84. Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E. 2006. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67:908–910.
85. Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, Sidransky E. 2005. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 42:e37.
86. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E. 2008. The spectrum of Parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353–1357.
87. Goker-Alpan O, Masdeu JC, Kohn PD, Ianni A, Lopez G, Groden C, Chapman MC, Cropp B, Eisenberg DP, Maniwang ED, Davis J, Wiggs E, et al. 2012. The neurobiology of glucocerebrosidase-associated Parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain 135:2440–2448.
88. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. 2004. Parkinsonism among Gaucher disease carriers. J Med Genet 41:937–940.
89. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. 2010. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120:641–649.
90. Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S. 2004. The mitochondrial arts protein promotes apoptosis through targeting xiap. EMBO J 23:1627–1635.
91. Grabowski GA, Horowitz M. 1997. Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 10:635–656.
92. Grosbois B, Revest M, Decaux O, Sebillot M. 2006. [Treatment of Gaucher disease: enzyme replacement therapy and emerging therapies (chemical chaperone and gene therapy)]. Ann Biol Clin (Paris) 64:600–602.
93. Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. 2009. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18:770–777.
94. Holleran WM, Takagi Y, Menon GK, Jackson SM, Lee JM, Feingold KR, Elias PM. 1994. Permeability barrier requirements regulate epidermal beta-glucocerebrosidase. J Lipid Res 35:905–912.
95. Horowitz M, Pasmanik-Chor M, Borochowitz Z, Falik-Zaccai T, Heldmann K, Carmi R, Parvari R, Beit-Or H, Goldman B, Peleg L, Levy-Lahad E, Renbaum P, et al. 1998. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 12:240–244.
96. Hruska KS, LaMarca ME, Scott CR, Sidransky E. 2008. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 29:567–583.
97. Imai Y, Soda M, Hatakeyama S, Akagi T, Hashikawa T, Nakayama KI, Takahashi R. 2002. Chip is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell 10:55–67.
98. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 105:891–902.
99. Imai Y, Soda M, Takahashi R. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661–35664.
100. Ivatt RM, Whitworth AJ. 2014. SREBF1 links lipogenesis to mitophagy and sporadic Parkinson disease. Autophagy 10:1476–1477.
101. Joosten A, Decroocq C, de Sousa J, Schneider JP, Etame E, Bodlenner A, Butters TD, Compain P. 2014. A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease. Chembiochem 15:309–319.
102. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L. 2009. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 452:87–89.
103. Kato A, Miyauchi S, Kato N, Nash RJ, Yoshimura Y, Nakagome I, Hirono S, Takahata H, Adachi I. 2011. Docking and SAR studies of D- and L-isofagomine isomers as human beta-glucocerebrosidase inhibitors. Bioorg Med Chem 19:3558–3568.
104. Katzen HL, Levin BE, Weiner W. 2006. Side and type of motor symptom influence cognition in Parkinson's disease. Mov Disord 21:1947–1953.
105. Kaufman RJ, Back SH, Song B, Han J, Hassler J. 2010. The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in beta-cells. Diabetes Obes Metab 12(Suppl 2):99–107.
106. Kemeny S, Dery D, Loboda Y, Rovner M, Lev T, Zuri D, Finberg JP, Larisch S. 2012. Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. PLoS One 7:e38837.
107. Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ, Piccini P. 2002. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125:2248–2256.
108. Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N, Lees AJ. 2004. Olfaction differentiates parkin disease from early-onset Parkinsonism and Parkinson disease. Neurology 62:1224–1226.
109. Khanna R, Benjamin ER, Pellegrino L, Schilling A, Rigat BA, Soska R, Nafar H, Ranes BE, Feng J, Lun Y, Powe AC, Palling DJ, et al. 2010. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 277:1618–1638.
110. Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. 2006. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281:16193–16196.
111. Ko HS, von Coelln R, Sriram SR, Kim SW, Chung KK, Pletnikova O, Troncoso J, Johnson B, Saffary R, Goh EL, Song H, Park BJ, et al. 2005. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25:7968–7978.
112. Kondoh K, Hineno T, Sano A, Kakimoto Y. 1991. Isolation and characterization of prosaposin from human milk. Biochem Biophys Res Commun 181:286–292.
113. Kono S, Shirakawa K, Ouchi Y, Sakamoto M, Ida H, Sugiura T, Tomiyama H, Suzuki H, Takahashi Y, Miyajima H, Hattori N, Mizuno Y. 2007. Dopaminergic neuronal dysfunction associated with Parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 252:181–184.
114. Kornhaber GJ, Tropak MB, Maegawa GH, Tuske SJ, Coales SJ, Mahuran DJ, Hamuro Y. 2008. Isofagomine induced stabilization of glucocerebrosidase. Chembiochem 9:2643–2649.
115. Korschen HG, Yildiz Y, Raju DN, Schonauer S, Bonigk W, Jansen V, Kremmer E, Kaupp UB, Wachten D. 2013. The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J Biol Chem 288:3381–3393.
116. Kravtsova-Ivantsiv Y, Ciechanover A. 2012. Non-canonical ubiquitin-based signals for proteasomal degradation. J Cell Sci 125:539–548.
117. Lai E, Teodoro T, Volchuk A. 2007. Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda) 22:193–201.
118. Landon MR, Lieberman RL, Hoang QQ, Ju S, Caaveiro JM, Orwig SD, Kozakov D, Brenke R, Chuang GY, Beglov D, Vajda S, Petsko GA, et al. 2009. Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 23:491–500.
119. Larisch S, Yi Y, Lotan R, Kerner H, Eimerl S, Tony Parks W, Gottfried Y, Birkey Reffey S, de Caestecker MP, Danielpour D, Book-Melamed N, Timberg R, et al. 2000. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol 2:915–921.
120. Lee YJ, Kim SJ, Heo TH. 2011. Protective effect of catechin in type I Gaucher disease cells by reducing endoplasmic reticulum stress. Biochem Biophys Res Commun 413:254–258.
121. Lei K, Ninomiya H, Suzuki M, Inoue T, Sawa M, Iida M, Ida H, Eto Y, Ogawa S, Ohno K, Suzuki Y. 2007. Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease. Biochim Biophys Acta 1772:587–596.
122. Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honore A, Rivaud S, Vidailhet M, et al. 2010. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 20:202–210.
123. Li Z, Li T, Dai S, Xie X, Ma X, Zhao W, Zhang W, Li J, Wang PG. 2013. New insights into the pharmacological chaperone activity of C2-substituted glucoimidazoles for the treatment of Gaucher disease. Chembiochem 14:1239–1247.
124. Lieberman RL, D'Aquino J A, Ringe D, Petsko GA. 2009. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48:4816–4827.
125. Lieberman RL, Wustman BA, Huertas P, Powe AC Jr., Pine CW, Khanna R, Schlossmacher MG, Ringe D, Petsko GA. 2007. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3:101–107.
126. Lin H, Sugimoto Y, Ohsaki Y, Ninomiya H, Oka A, Taniguchi M, Ida H, Eto Y, Ogawa S, Matsuzaki Y, Sawa M, Inoue T, et al. 2004. N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochim Biophys Acta 1689:219–228.
127. Liu YC. 2007. The E3 ubiquitin ligase ITCH in T cell activation, differentiation, and tolerance. Semin Immunol 19:197–205.
128. Lu J, Chiang J, Iyer RR, Thompson E, Kaneski CR, Xu DS, Yang C, Chen M, Hodes RJ, Lonser RR, Brady RO, Zhuang Z. 2010. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci USA 107:21665–21670.
129. Lu J, Yang C, Chen M, Ye DY, Lonser RR, Brady RO, Zhuang Z. 2011. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci USA 108:21200–21205.
130. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M, Rosenbaum H Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, et al. 2010a. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. 2010. Blood 116: 893–899.
131. Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, et al. 2010b. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116: 4095–4098. Correction in: Blood. 117: 5551.
132. Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, Zimran A, Angell J, Ross L, Puga AC, Peterschmitt JM. 2014. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis. 53:274–276.
133. Luan Z, Li L, Higaki K, Nanba E, Suzuki Y, Ohno K. 2012. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev 35:317–322.
134. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. 2004. Glucocerebrosidase mutations in subjects with Parkinsonism. Mol Genet Metab 81:70–73.
135. Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D, Tang L, Kornhaber GJ, Hamuro Y, Clarke JT, Mahuran DJ. 2009. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284:23502–23516.
136. Malec-Litwinowicz M, Rudzinska M, Szubiga M, Michalski M, Tomaszewski T, Szczudlik A. 2014. Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients. Neurol Neurochir Pol 48:258–261.
137. Mao XY, Burgunder JM, Zhang ZJ, An XK, Zhang JH, Yang Y, Li T, Wang YC, Chang XL, Peng R. 2010. Association between GBA L444P mutation and sporadic Parkinson's disease from mainland china. Neurosci Lett 469:256–259.
138. Maor G, Cabasso O, Krivoruk O, Rodriguez J, Steller H, Segal D, Horowitz M. 2016. The contribution of mutant GBA to the development of Parkinson disease in Drosophila. Hum Mol Genet. [Epub ahead of print]
139. Maor G, Filocamo M, Horowitz M. 2013a. ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease. Hum Mol Genet 22:1316–1327.
140. Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M. 2013b. Unfolded protein response in Gaucher disease: from human to drosophila. Orphanet J Rare Dis 8:140.
141. Martin BM, Tsuji S, LaMarca ME, Maysak K, Eliason W, Ginns EI. 1988. Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector. DNA 7:99–106.
142. Massey AC, Kiffin R, Cuervo AM. 2006a. Autophagic defects in aging: looking for an "emergency exit"? Cell Cycle 5:1292–1296.
143. Massey AC, Zhang C, Cuervo AM. 2006b. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol 73:205–235.
144. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. 2011. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146:37–52.
145. McGlinchey RP, Lee JC. 2013. Emerging insights into the mechanistic link between alpha-synuclein and glucocerebrosidase in Parkinson's disease. Biochem Soc Trans 41:1509–1512.
146. McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, Foltynie T, Cooper JM, Abramov AY, Gegg M, Schapira AH. 2014. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137:1481–1495.
147. Melino G, Gallagher E, Aqeilan RI, Knight R, Peschiaroli A, Rossi M, Scialpi F, Malatesta M, Zocchi L, Browne G, Ciechanover A, Bernassola F. 2008. Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ 15:1103–1112.
148. Melino G, Knight RA, Cesareni G. 2006. Degradation of p63 by ITCH. Cell Cycle 5:1735–1739.
149. Mendre C, Mouillac B. 2010. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]. Med Sci (Paris) 26:627–635.
150. Michael D, Oren M. 2003. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49–58.
151. Mistry PK, Liu J, Sun L, Chuang WL, Yuen T, Yang R, Lu P, Zhang K, Li J, Keutzer J, Stachnik A, Mennone A, et al. 2014. Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci USA 111:4934–4939.
152. Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Durr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, et al. 2015. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol 2:417–426.
153. Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, Fukuda Y, Date H, Iwata A, Yamamoto M, Hattori N, Murata M, et al. 2009. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66:571–576.
154. Motabar O, Huang W, Marugan JJ, Southall N, DeBernardi M, Zheng W, Sidransky E. 2010. Identification of modulators of the N370S mutant form of glucocerebrosidase as a potential therapy for Gaucher disease—chemotype 2. Probe reports from the NIH molecular libraries program [Internet]. Bethesda, MD: National Center for Biotechnology Information (US).
155. Mu TW, Fowler DM, Kelly JW. 2008. Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6:e26.
156. Muller A, Reichmann H, Livermore A, Hummel T. 2002. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 109:805–811.
157. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM. 2014. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137:834–848.
158. Murphy KE, Halliday GM. 2014. Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy 10:1350–1351.
159. Nakatsukasa K, Kamura T, Brodsky JL. 2014. Recent technical developments in the study of ER-associated degradation. Curr Opin Cell Biol 29:82–91.
160. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, Morris CM, Theuns J, Crosiers D, Cras P, Engelborghs S, De Deyn PP, et al. 2013. A multicenter study of glucocerebrosidase mutations in dementia with lewy bodies. JAMA Neurol 70:727–735.
161. Needham PG, Brodsky JL. 2013. How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD. Biochim Biophys Acta 1833:2447–2457.
162. Neufeld EF. 2006. Enzyme replacement therapy—a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford, UK: Oxford PharmaGenesis.
163. Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, et al. 2009. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132:1783–1794.
164. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T. 2009. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72:310–316.
165. Nuzhnyi E, Emelyanov A, Boukina T, Usenko T, Yakimovskii A, Zakharova E, Pchelina S. 2015. Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease. Mov Disord 30:989–991.
166. O'Brien JS, Kishimoto Y. 1991. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 5:301–308.
167. Offman MN, Krol M, Silman I, Sussman JL, Futerman AH. 2010. Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. J Biol Chem 285:42105–42114.
168. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, et al. 2011. A more efficient method to generate integration-free human IPS cells. Nat Methods 8:409–412.
169. Ong DS, Mu TW, Palmer AE, Kelly JW. 2010. Endoplasmic reticulum CA2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol 6:424–432.
170. Ortolano S, Vieitez I, Navarro C, Spuch C. 2014. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov 8:9–25.
171. Orwig SD, Tan YL, Grimster NP, Yu Z, Powers ET, Kelly JW, Lieberman RL. 2011. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-beta-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease. Biochemistry 50:10647–10657.
172. Osellame LD, Duchen MR. 2013. Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases. Autophagy 9:1633–1635.
173. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, Waddington SN, Schapira AH, Duchen MR. 2013. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 17:941–953.
174. Panicker LM, Miller D, Awad O, Bose V, Lun Y, Park TS, Zambidis ET, Sgambato JA, Feldman RA. 2014. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development. Stem Cells 32:2338–2349.
175. Parenti G. 2009. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 1:268–279.
176. Parnetti L, Balducci C, Pierguidi L, De Carlo C, Peducci M, D'Amore C, Padiglioni C, Mastrocola S, Persichetti E, Paciotti S, Bellomo G, Tambasco N, et al. 2009. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in dementia with Lewy bodies. Neurobiol Dis 34:484–486.
177. Passmore LA, Barford D. 2004. Getting into position: the catalytic mechanisms of protein ubiquitylation. Biochem J 379:513–525.
178. Peall K, Robertson NP. 2013. Parkinsonism, dementia and glucocerebrosidase mutations. J Neurol 260:1441–1444.
179. Pearce RK, Hawkes CH, Daniel SE. 1995. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 10:283–287.
180. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503–533.
181. Platt FM. 2014. Sphingolipid lysosomal storage disorders. Nature 510:68–75.
182. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD, Cox TM, Lachmann RH, Hollak C, Aerts JM, Van Weely S, Hrebicek M, et al. 2001. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24:275–290.
183. Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD. 1997. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276:428–431.
184. Qiu L, Joazeiro C, Fang N, Wang HY, Elly C, Altman Y, Fang D, Hunter T, Liu YC. 2000. Recognition and ubiquitination of NOTCH by ITCH, a HECT-type E3 ubiquitin ligase. J Biol Chem 275:35734–35737.
185. Ransmayr G, Poewe W, Plorer S, Gerstenbrand F, Leidlmair K, Mayr U. 1986. Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters. J Neural Transm 67:1–14.
186. Reczek D, Schwake M, Schroder J, Hughes H, Blanz J, Jin X, Brondyk W, Van Patten S, Edmunds T, Saftig P. 2007. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131:770–783.
187. Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, Zhang J. 2014. Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol 53:127–133.
188. Reiner O, Horowitz M. 1988. Differential expression of the human glucocerebrosidase-coding gene. Gene 73:469–478.
189. Ren Y, Zhao J, Feng J. 2003. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J Neurosci 23:3316–3324.
190. Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, Dolle F, Peschanski M, Hantraye P, Cesaro P, Samson Y, Remy P. 2002. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59:580–586.
191. Richard IH. 2005. Anxiety disorders in Parkinson's disease. Adv Neurol 96:42–55.
192. Richter F, Fleming SM, Watson M, Lemesre V, Pellegrino L, Ranes B, Zhu C, Mortazavi F, Mulligan CK, Sioshansi PC, Hean S, De La Rosa K, et al. 2014. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11:840–856.
193. Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, et al. 2008. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 255:255–264.
194. Rogers S, Patnaik S, Schoenen F, Zheng W, Choi J, Motabar O, Southall N, Westbroek W, Goldin E, Sidransky E, Leister W, Marugan JJ, et al. 2010. Discovery, SAR, and biological evaluation of non-inhibitory chaperones of glucocerebrosidase. Probe reports from the NIH molecular libraries program [Internet]. Bethesda, MD: National Center for Biotechnology Information (US).
195. Ron I, Horowitz M. 2005. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14:2387–2398.
196. Ron I, Rapaport D, Horowitz M. 2010. Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease. Hum Mol Genet 19:3771–3781.
197. Rorman EG, Scheinker V, Grabowski GA. 1992. Structure and evolution of the human prosaposin chromosomal gene. Genomics 13:312–318.
198. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, Taylor JS, Cole JA, Zimran A, Weinreb NJ. 2011. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher registry. Blood Cells Mol Dis 46:95–102.
199. Sanchez-Olle G, Duque J, Egido-Gabas M, Casas J, Lluch M, Chabas A, Grinberg D, Vilageliu L. 2009. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cells Mol Dis 42:159–166.
200. Sano A, Hineno T, Mizuno T, Kondoh K, Ueno S, Kakimoto Y, Inui K. 1989. Sphingolipid hydrolase activator proteins and their precursors. Biochem Biophys Res Commun 165:1191–1197.
201. Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, Shihabuddin LS. 2011. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci USA 108:12101–12106.
202. Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG. 2012. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neurodegener Dis 10:195–202.
203. Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, Tagliati M, Condefer K, Palmese C, Bruggemann N, Klein C, Roe A, et al. 2010. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 25:1364–1372.
204. Sawkar AR, Adamski-Werner SL, Cheng WC, Wong CH, Beutler E, Zimmer KP, Kelly JW. 2005. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 12:1235–1244.
205. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW. 2002. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99:15428–15433.
206. Sawkar AR, D'Haeze W, Kelly JW. 2006. Therapeutic strategies to ameliorate lysosomal storage disorders—a focus on Gaucher disease. Cell Mol Life Sci 63:1179–1192.
207. Schimke RT, Alt FW, Kellems RE, Kaufman RJ, Bertino JR. 1978. Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. Cold Spring Harb Symp Quant Biol 42(Pt 2):649–657.
208. Schmitz M, Alfalah M, Aerts JM, Naim HY, Zimmer KP. 2005. Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease. Int J Biochem Cell Biol 37:2310–2320.
209. Schneider JL, Cuervo AM. 2013. Chaperone-mediated autophagy: dedicated saviour and unfortunate victim in the neurodegeneration arena. Biochem Soc Trans 41:1483–1488.
210. Schroder M. 2006. The unfolded protein response. Mol Biotechnol 34:279–290.
211. Segarane B, Li A, Paudel R, Scholz S, Neumann J, Lees A, Revesz T, Hardy J, Mathias CJ, Wood NW, Holton J, Houlden H. 2009. Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. Neurology 72:1185–1186.
212. Serra-Vinardell J, Diaz L, Guitierrez-de Teran H, Sanchez-Olle G, Bujons J, Michelakakis H, Mavridou I, Aerts JM, Delgado A, Grinberg D, Vilageliu L, Casas J. 2014. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease. Int J Biochem Cell Biol 54:245–254.
213. Shanmuganathan M, Britz-McKibbin P. 2011. Inhibitor screening of pharmacological chaperones for lysosomal beta-glucocerebrosidase by capillary electrophoresis. Anal Bioanal Chem 399:2843–2853.
214. Shanmuganathan M, Britz-McKibbin P. 2012. Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation. Biochemistry 51:7651–7653.
215. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM. 2011. Paris (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144:689–702.
216. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, et al. 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361:1651–1661.
217. Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E. 2008. Association between Parkinson's disease and glucocerebrosidase mutations in brazil. Parkinsonism Relat Disord 14:58–62.
218. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. 2003. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37:735–749.
219. Steet R, Chung S, Lee WS, Pine CW, Do H, Kornfeld S. 2007. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol 73:1376–1383.
220. Sun Y, Florer J, Mayhew CN, Jia Z, Zhao Z, Xu K, Ran H, Liou B, Zhang W, Setchell KD, Gu J, Grabowski GA. 2015. Properties of neurons derived from induced pluripotent stem cells of Gaucher disease type 2 patient fibroblasts: potential role in neuropathology. PLoS One 10:e0118771.
221. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA. 2010. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394l) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19:1088–1097.
222. Sun Y, Quinn B, Xu YH, Leonova T, Witte DP, Grabowski GA. 2006. Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res 47:2161–2170.
223. Sun Y, Ran H, Liou B, Quinn B, Zamzow M, Zhang W, Bielawski J, Kitatani K, Setchell KDR, Hannun YA, Grabowski GA. 2011. Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse. PLoS One. 2011; 6(4): e19037.
224. Suzuki H, Hosouchi Y, Sasaki S, Araki K, Kubo N, Watanabe A, Kuwano H. 2013. Reconstruction of the hepatic artery with the middle colic artery is feasible in distal pancreatectomy with celiac axis resection: a case report. World J Gastrointest Surg 5:224–228.
225. Suzuki M, Fujikake N, Takeuchi T, Kohyama-Koganeya A, Nakajima K, Hirabayashi Y, Wada K, Nagai Y. 2015. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant alpha-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet 24:6675–6686.
226. Suzuki Y. 2013. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease. Brain Dev 35:515–523.
227. Suzuki Y, Ogawa S, Sakakibara Y. 2009. Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Medicin Chem 3:7–19.
228. Swaminathan G, Tsygankov AY. 2006. The CBL family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209:21–43.
229. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, et al. 2010. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 207:2817–2830.
230. Tan EK, Tong J, Fook-Chong S, Yih Y, Wong MC, Pavanni R, Zhao Y. 2007. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64:1056–1058.
231. Tan YL, Genereux JC, Pankow S, Aerts JM, Yates JR, 3rd, Kelly JW. 2014. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. Chem Biol 21:967–976.
232. Tanaka K, Suzuki T, Hattori N, Mizuno Y. 2004. Ubiquitin, proteasome and parkin. Biochim Biophys Acta 1695:235–247.
233. Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, Niwa A, Nishikomori R, Kambe N, Hara H, Mitsuyama M, Morone N, et al. 2012. Induced pluripotent stem cells from cinca syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood 120:1299–1308.
234. Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, Fillano JJ, Sidransky E. 2001. Gaucher disease and Parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313–321.
235. Tiscornia G, Vivas EL, Matalonga L, Berniakovich I, Barragan Monasterio M, Eguizabal C, Gort L, Gonzalez F, Ortiz Mellet C, Garcia Fernandez JM, Ribes A, Veiga A, et al. 2013. Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet 22:633–645.
236. Todde V, Veenhuis M, van der Klei IJ. 2009. Autophagy: principles and significance in health and disease. Biochim Biophys Acta 1792:3–13.
237. Tomer R, Levin BE, Weiner WJ. 1993. Side of onset of motor symptoms influences cognition in Parkinson's disease. Ann Neurol 34:579–584.
238. Trapero A, Llebaria A. 2014. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease? Future Med Chem 6:975–978.
239. Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH. 2012. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain 135:1724–1735.
240. Vitner EB, Futerman AH. 2013. Neuronal forms of Gaucher disease. Handb Exp Pharmacol 216:405–419.
241. Vitner EB, Salomon R, Farfel-Becker T, Meshcheriakova A, Ali M, Klein AD, Platt FM, Cox TM, Futerman AH. 2014. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat Med 20:204–208.
242. Walter P, Ron D. 2011. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334:1081–1086.
243. Wang F, Chou A, Segatori L. 2011. Lacidipine remodels protein folding and CA2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chem Biol 18:766–776.
244. Wang X, Huang T, Bu G, Xu H. 2014. Dysregulation of protein trafficking in neurodegeneration. Mol Neurodegener 9:31.
245. Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB. 2008. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 17:469–477.
246. Westervelt HJ, Stern RA, Tremont G. 2003. Odor identification deficits in diffuse Lewy body disease. Cogn Behav Neurol 16:93–99.
247. Willemsen R, van Dongen JM, Ginns EI, Sips HJ, Schram AW, Tager JM, Barranger JA, Reuser AJ. 1987. Ultrastructural localization of glucocerebrosidase in cultured Gaucher's disease fibroblasts by immunocytochemistry. J Neurol 234:44–51.
248. Wu YR, Chen CM, Chao CY, Ro LS, Lyu RK, Chang KH, Lee-Chen GJ. 2007. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 78:977–979.
249. Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. 2011. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102:436–447.
250. Yamanaka S. 2010. Patient-specific pluripotent stem cells become even more accessible. Cell Stem Cell 7:1–2.
251. Yamanaka S. 2012. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10:678–684.
252. Yang C, Rahimpour S, Lu J, Pacak K, Ikejiri B, Brady RO, Zhuang Z. 2013. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci USA 110:966–971.
253. Yang C, Wang H, Zhu D, Hong CS, Dmitriev P, Zhang C, Li Y, Ikejiri B, Brady RO, Zhuang Z. 2015. Mutant glucocerebrosidase in Gaucher disease recruits HSP27 to the HSP90 chaperone complex for proteasomal degradation. Proc Natl Acad Sci USA 112:1137–1142.
254. Yildiz Y, Hoffmann P, Vom Dahl S, Breiden B, Sandhoff R, Niederau C, Horwitz M, Karlsson S, Filocamo M, Elstein D, Beck M, Sandhoff K, et al. 2013. Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease. Orphanet J Rare Dis 8:151.
255. Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, Hammer RE, Hamra FK, Matern S, Russell DW. 2006. Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest 116:2985–2994.
256. Yu L, Ikeda K, Kato A, Adachi I, Godin G, Compain P, Martin O, Asano N. 2006. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease. Bioorg Med Chem 14:7736–7744.
257. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. 2000. Parkin functions as an E2-dependent ubiquitin–protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97:13354–13359.
258. Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, Simeonov A, Goldin E, Auld D, LaMarca ME, Inglese J, Austin CP, Sidransky E. 2007. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci USA 104:13192–13197.
259. Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, Goker-Alpan O, LaMarca ME, Sidransky E. 2007. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91:195–200.
260. Zimmer KP, le Coutre P, Aerts HM, Harzer K, Fukuda M, O'Brien JS, Naim HY. 1999. Intracellular transport of acid beta-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation). J Pathol 188:407–414.
261. Zimran A, Altarescu G, Elstein D. 2013. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis 50:134–137.
262. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, et al. 2011. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118:5767–5773.